INTRODUCTION
Congenital heart disease (CHD) is the most common type of birth defect, accounting for one-third of all major congenital anomalies, and represents a major public health issue [1, 2] .
The reported total CHD prevalence has increased substantially over the last century, most likely due to improved diagnostic methods and screening modalities, although prevalence rates vary widely among studies worldwide [2] . It is estimated that CHD affects 9 in 1000 children, although significant geographical differences in prevalence have been reported [2] . A systematic review of the literature found that Europe had the second highest reported total CHD birth prevalence [8.2 per 1000 live births, 95% confidence interval (CI) 8.1-8.3]; this was significantly higher than in North America (6.9 per 1000 live births, 95% CI 6.7-7.1; P\0.001) [2] .
Children with CHD are at risk for increased morbidity from viral lower respiratory tract infection (LRTI) because of anatomical cardiovascular lesions, which can cause pulmonary hypertension leading to increased ventilation-perfusion mismatch and, ultimately, hypoxia [3] . Globally, RSV is the most common cause of childhood acute LRTIs, with at least 3.4 million episodes necessitating admission to hospital each year [4] . CHD limits an infant's ability to increase cardiac output, and concurrently oxygen delivery can be severely limited [5] . If an infant develops respiratory syncytial virus (RSV) LRTI, oxygen uptake can be further impaired and the work of breathing in these infants with compromised cardiac reserve is increased [5] . Infants and young children with CHD are especially at risk for severe disease and hospitalization and, in some instances, may require admission to the intensive care unit (ICU), supplemental oxygen therapy and prolonged mechanical ventilation [5, 6] . Furthermore, RSV LRTI can cause mortality in the immediate period surrounding either palliative or corrective cardiac surgery employing cardiopulmonary bypass [7] . Hemodynamically significant CHD (HS-CHD) in association with RSV infection can lead to prolonged hospitalization [8] and an increased risk of death [9] . RSV infection may also delay corrective cardiac surgery [10] , potentially increasing CHD-associated morbidity.
Since treatment is largely supportive and there is no effective vaccine for RSV, prevention is critically important in this vulnerable population. Current guidelines focus on infants at high risk for severe RSV infection and recommend RSV immunoprophylaxis in children with HS-CHD aged \12 months at the start of the RSV season [11] [12] [13] . However, since a number of children with residual HS-CHD postoperatively or awaiting cardiac transplant still remain at risk for severe RSV LRTI, some position statements continue to support RSV prophylaxis in the second year of life [14] [15] [16] [17] .
Identification of risk factors for RSV hospitalization (RSVH) and implementation of targeted prophylaxis are important to reduce the burden of severe RSV disease on inpatient and outpatient services and to improve patient outcomes. A vast amount of literature on RSV has accumulated over the past 20 years, and to review, evaluate and interpret this evidence a panel of experts in RSV from the United States, Canada and Europe formed REGAL (RSV Evidence-a Geographical Archive of the Literature) [18] . REGAL provides a comprehensive understanding on a range of topics on RSV LRTI within Western societies. This, the fourth paper in the REGAL series [18] [19] [20] , identifies and evaluates the risks and associated morbidity and mortality of severe RSV LRTI in infants and young children with CHD.
METHODS

Study Objective
REGAL encompassed seven specific research questions on RSV related to the following topics: overall epidemiology [18] , prematurity [19] , chronic lung disease (CLD)/ bronchopulmonary dysplasia (BPD) [20] , CHD, long-term respiratory morbidity, other high-risk
groups (e.g., Down syndrome), and prevention, management and future perspectives. For the purposes of REGAL, Western countries were defined as the United States, Canada, and Europe (including Turkey and the Russian Federation). The overall methodology for REGAL was described in full in the first publication [18] . In summary, to address each question a systematic review of the medical literature electronically indexed in PubMed, EMBASE, and the Cochrane Library was performed. In addition, clinicaltrials.gov was searched for any relevant studies that are currently being conducted.
Literature Search
The specific research question for this review was: ''What is the predisposition and associated For completeness, all reports describing infants with CHD, regardless of definition, were considered for inclusion in this review in order to elucidate the additional risk of RSV infection in children with significant cardiac issues at birth. To facilitate interpretation of the data, the definitions of CHD used in individual studies, where stated, were documented.
Outcomes of Interest
Key outcomes for this review included: hospitalization rates due to severe RSV infection; hospital length of stay (LOS); ICU admission and LOS; oxygen requirement; need for and duration of mechanical ventilation and/ or non-invasive ventilation; and case fatality rates.
Evaluation of Data
All included studies were graded according to the Oxford Centre for Evidence-Based Medicine Levels of Evidence [24, 25] (Supplementary Material 1-REGAL Protocol). Each study was also subject to a risk of bias assessment using the RTI Item Bank (score of 1 = very high risk of bias; score of 12 = very low risk of bias) for observational studies [26] . No quantitative data synthesis was conducted due to heterogeneity between studies in terms of design, patient populations, RSV testing, recording and availability of outcomes, and differences in clinical practice between countries and over time.
Statement of Ethics Compliance
The analysis in this article is based on previously published studies and does not involve any new studies of human subjects performed by any of the authors.
RESULTS
Articles Selected
From a total of 1325 publications, 38 studies were included in the final review: 31 identified from the database searches and a further 7 from reference lists/other sources ( Fig. 1 ). Details of all 36 studies, including evidence grades and risk of bias assessments, can be found in the online supplement.
Incidence of RSVH in Infants and Children with CHD
CHD, irrespective of hemodynamic significance, poses a significant risk for severe RSV infection requiring hospitalization [5, 8, . RSVH rates ranged from 14 to 357 per 1000 (Table 1) , although comparison of these studies is difficult as a result of differences in the study populations, some of which were not specifically CHD patients, methods used and inclusion criteria. [30] . A significant decrease in frequency of RSV LRTI and RSVH was also observed with increasing age in the Canadian PICNIC study [36] . The RSVH rates in children with CHD aged 0-3, 3-6, 6-12 and 12-24 months were 360, 60, 0 and 10 per 1000, respectively [36] . In contrast, Altman et al. [10] found that RSV disease necessitating hospitalization occurred in children with CHD well into the second year of life. The average age at admission for RSV infection in children with CHD was 16 ± 12 months, with children [12 months of age accounting for 61% (34/ 56) of the cohort [10] . The aforementioned studies included data from 1989-2003 [10, 29, 30, 36, 38] . It might be expected that, with corrective surgery now mostly occurring in the first few months of life, rates of RSVH in the second year of life would be lower than what has been reported here. However, we were unable to identify any data to support this assertion. There is recently published evidence from the US and Canada which indicates that infants with complex cardiac conditions remain at substantial risk of RSVH in the second year of life [48, 49] .
In multivariate analyses, CHD has been found to be an independent risk factor for RSVH [27, 34, 38, 50] an increased risk of RSV-related LRTI hospitalization in multivariable analyses (P = 0.0077) [50] . Verification of non-hsCHD as an independently significant risk factor for RSVH in non-premature populations is required.
Morbidity and Healthcare Resource Utilization
The disease burden associated with RSVH in infants and young children (\6 years) with CHD is considerable ( Table 2 ). Length of stay in hospital and ICU admissions vary among [48] .
Nosocomial outbreaks of RSV infection in ICUs also represent an important cause of morbidity in this specific, high-risk population [53, 54] . Children on long-term mechanical ventilation may acquire RSV infection by transmission through droplets or caregivers and face an increased risk of a severe course of RSV infection [53] . A German study prospectively documented 1568 RSV infections in 1541 pediatric patients of whom 20 (1.3%) had acquired the RSV infection while being treated by mechanical intervention for other reasons. Thirty-five percent of the children (median age 4.2 months, range 0.5-97 months) who acquired the RSV infection whilst mechanically ventilated had CHD [53] . In a UK study reporting on a RSV outbreak in a PICU, 27.8% (15/54) of the children acquired the RSV infection whilst in the PICU [54] . In this study, PICU-acquired RSV infection was defined as having occurred when a child admitted to the PICU was RSV-negative or from whom no samples were taken because they did not exhibit signs of bronchiolitis, and who then was found to be RSV-positive C5 days after the admission [54] . Nosocomially-acquired RSV infection has also been documented during hospitalization in infants aged \2 years in an Italian study [45] . [55] . The nature, incidence and impact of long-term respiratory morbidity associated with RSVH in infancy in Western countries will be covered in more detail in a subsequent publication in the REGAL series.
Impact of RSV Infection on Cardiac
Surgery for CHD Surgical outcomes in children with CHD have improved over the past two decades. However, a significant number of children are exposed to RSV, which can result in substantial morbidity and mortality [10, [56] [57] [58] . In a post hoc analysis of a multicenter, randomized trial [ 
Case Fatality Rates
Few studies have specifically investigated mortality due to RSV in young children with CHD. Available data from the published literature suggest that the case fatality rate for RSV is relatively low among infants and children with CHD in Western countries, ranging from 0 to 3.3% [5, 6, 8, 10, 30, 38-40, 42, 44, 47, 48, 52] .
In a retrospective, single-center study of 30 [48] . A study published in 2009, undertaken to determine the mortality rate and risk factors for death in children with severe RSV infection, found that pre-existing disease/comorbidity, in particular multiple pre-existing diseases and cardiac anomaly, was associated with a significantly higher risk of death from severe RSV infection [9] . All the RSV deaths had pre-existing medical conditions/comorbidity (27% cardiac lesions) [9] . Similar data come from a recently published US study which reported that the majority (76-79%) of RSV-associated deaths occurred in infants with complex chronic conditions [60] . Cardiovascular conditions were the most frequent single chronic condition identified, being associated with 37-45% of all RSV-related deaths [60] .
Limitations
It should be recognised that the evolving definitions of CHD over time may have affected comparisons between studies and interpretation of results. Additionally, it is difficult to measure the impact of improved surgical practice in this population on the Most studies have focussed on HS-CHD, but the definition across the reviewed studies is not standardized. Recent data suggest that infants with CHD that is not hemodynamically significant are also at increased risk of RSVH and suffer a substantial burden of RSV disease. 
Moreover
